On The Radar – 17th Edition
By
Finance leaders are shifting focus from headline list prices to “net price,” where rebates and fees can reduce costs by up to 60%. The challenge is that these true costs are often buried in complex financial arrangements.
➡ Why it matters: Employers who cannot see net cost clearly cannot manage pharmacy spend effectively.
A federal lawsuit against JPMorgan is moving forward, alleging failure to properly manage pharmacy benefit costs. The case reinforces a broader trend of ERISA litigation targeting employers for not actively overseeing drug pricing.
➡ Why it matters: Pharmacy oversight is now a fiduciary responsibility with real legal consequences.
Calls for transparency continue to intensify as critics highlight how PBMs profit from spread pricing and retained rebates. Industry consolidation has further concentrated control among a small number of players.
➡ Why it matters: Misaligned incentives within the supply chain remain a major driver of rising drug costs.
New federal reforms are redefining expectations for plan sponsors. With increased access to pricing data comes increased accountability to act on it.
➡ Why it matters: Employers can no longer rely on vendors alone. Active governance is becoming the standard.
Employers are moving away from opaque, rebate-driven contracts toward transparent, pass-through models with audit rights and market checks built in.
➡ Why it matters: Contract structure is quickly becoming one of the most important levers in controlling pharmacy spend.
Regulators are exploring expanding over-the-counter access for more medications to improve affordability and reduce system friction. However, safety concerns and loss of insurance coverage complicate the transition.
➡Why it matters: Expanding access could lower barriers, but may shift more cost responsibility to patients.
Federal price negotiations are lowering costs for select drugs, while many others continue to see annual price increases. The result is a mixed pricing environment across the market.
➡Why it matters: Employers must navigate both downward pressure and continued upward trends simultaneously.
Healthcare costs in the U.S. continue to be driven by price, not utilization. Lack of standardization and transparency leaves patients and employers unable to act as informed consumers.
➡Why it matters: Until unit pricing is addressed, cost pressures will remain systemic.
The orphan drug market is projected to exceed $350 billion, fueled by innovation in gene and cell therapies. While clinically transformative, these treatments come with extremely high costs.
➡ Why it matters: Breakthrough therapies will continue to challenge traditional funding models for employer plans.
Industry scrutiny is intensifying around how drug prices are actually set. While manufacturers often point to R&D costs, data suggests pricing is frequently disconnected from development investment, with Americans paying significantly more than patients globally for the same medications.
➡ Why it matters: The growing gap between perceived cost and actual cost is fueling both regulatory pressure and employer demand for transparency.
A combination of limited price controls, patent strategies, and intermediary dynamics continues to keep U.S. drug prices elevated compared to global markets.
➡ Why it matters: Without structural reform, pricing disparities are unlikely to resolve on their own.
The rapid rise of GLP-1 medications is forcing employers to rethink coverage strategies, shifting toward tighter clinical oversight and more integrated care models.
➡ Why it matters: High-demand therapies require proactive management to balance access and financial impact.
Final Thoughts
The shift from list price to real price is exposing long-standing inefficiencies across the pharmacy ecosystem. At the same time, legal pressure, regulatory reform, and market dynamics are forcing employers to take a far more active role in managing pharmacy benefits. Those who embrace transparency and governance will be best positioned to navigate what comes next.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.